iMD Companies, Inc. (OTC: ICBU) announced today that it is in advanced due diligence to acquire a company in the mining sector while simultaneously engaging in active negotiations to purchase a target in the medical health space. The announcements were made via a press release issued by the company on June 18, 2026.
These potential acquisitions align with iMD’s strategy of acquiring revenue-generating businesses in established and high-potential industries. According to the company, the mining target represents continued expansion in natural resources, while the medical health acquisition would further strengthen the company’s presence in the healthcare sector.
“We are pleased with the progress on both fronts,” said Richard Wilson, CEO of iMD Companies, Inc. “These potential acquisitions reflect our disciplined approach to identifying assets that can deliver long-term value and sustainable growth for our shareholders.”
The company expects to complete due diligence and negotiations in the coming weeks and will provide further updates as material developments occur. iMD remains committed to transparency and timely communication with its shareholders. For more information on iMD, visit imdcompaniesinc.com or OTC Markets. Follow @imd_inc on X for real-time updates.
The importance of this news lies in iMD’s strategic pivot toward diversification across two distinct industries—mining and healthcare. For investors, this dual-track approach could mitigate risk by spreading exposure across sectors with different economic drivers. The mining sector, often tied to commodity cycles, offers potential for substantial returns during upswings, while healthcare provides steady demand irrespective of economic conditions. The successful completion of these acquisitions could enhance iMD’s revenue base and position it for long-term growth.
For the broader market, iMD’s moves reflect a trend among small-cap companies seeking to consolidate in fragmented industries. If the acquisitions materialize, they may signal confidence in the mining and medical health sectors, potentially attracting further investment. Shareholders of iMD will be watching closely, as the company has not disclosed specific financial terms or the names of the targets. The forward-looking statements in the press release caution that actual results may differ due to risks and uncertainties, underscoring the speculative nature of such announcements.
As iMD progresses through due diligence and negotiations, the coming weeks will be critical. The company has indicated it will provide updates on material developments, which will be key for investors assessing the likelihood of these deals closing. The outcome could set the stage for iMD’s next phase of growth and its ability to deliver on its promise of building shareholder value through targeted acquisitions.
